Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
RMTI logo RMTI
Upturn stock ratingUpturn stock rating
RMTI logo

Rockwell Medical Inc (RMTI)

Upturn stock ratingUpturn stock rating
$1.2
Last Close (24-hour delay)
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

10/14/2025: RMTI (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

2 Analysts rated it

Very few follow this stock; limited insights, higher-risk early investing.

1 Year Target Price $4

1 Year Target Price $4

Analysts Price Target For last 52 week
$4 Target price
52w Low $0.78
Current$1.2
52w High $5.15

Analysis of Past Performance

Type Stock
Historic Profit -27.89%
Avg. Invested days 22
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 2.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 10/14/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 39.25M USD
Price to earnings Ratio -
1Y Target Price 4
Price to earnings Ratio -
1Y Target Price 4
Volume (30-day avg) 2
Beta 1.73
52 Weeks Range 0.78 - 5.15
Updated Date 10/13/2025
52 Weeks Range 0.78 - 5.15
Updated Date 10/13/2025
Dividends yield (FY) -
Basic EPS (TTM) -0.07

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Revenue by Geography

Geography revenue - Year on Year

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -2.39%
Operating Margin (TTM) -8.39%

Management Effectiveness

Return on Assets (TTM) -1.53%
Return on Equity (TTM) -7.79%

Valuation

Trailing PE -
Forward PE 59.17
Enterprise Value 37245725
Price to Sales(TTM) 0.45
Enterprise Value 37245725
Price to Sales(TTM) 0.45
Enterprise Value to Revenue 0.42
Enterprise Value to EBITDA 30.21
Shares Outstanding 34430352
Shares Floating 28141993
Shares Outstanding 34430352
Shares Floating 28141993
Percent Insiders 14.07
Percent Institutions 17.19

ai summary icon Upturn AI SWOT

Rockwell Medical Inc

stock logo

Company Overview

overview logo History and Background

Rockwell Medical Inc. was founded in 1995. It is a biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative therapies and services.

business area logo Core Business Areas

  • Drug Products: Focuses on developing and commercializing drug products for patients with kidney disease. The company's main products are Triferic AVNU for hemodialysis and Triferic Dialysate for peritoneal dialysis, which are iron replacement therapies that maintain hemoglobin levels and reduce the need for erythropoiesis-stimulating agents (ESAs).
  • Equipment and Services: Previously offered dialysis concentrates, dialysis equipment, and services; however, the company divested its dialysis business in 2023.

leadership logo Leadership and Structure

Mark Strobeck, Ph.D. is the President and CEO. The company is structured with various departments including research & development, clinical operations, commercial operations, and finance.

Top Products and Market Share

overview logo Key Offerings

  • Triferic AVNU: Triferic AVNU is an FDA-approved intravenous iron maintenance therapy indicated for the treatment of iron deficiency in adult patients with hemodialysis-dependent chronic kidney disease (CKD). While specific market share data is dynamic, Triferic competes with traditional IV iron products. Competitors include Vifor Pharma, AMAG Pharmaceuticals (now part of Covis Pharma), and Akebia Therapeutics. Revenue data specific to Triferic AVNU is not publicly available on a product-by-product basis but is incorporated into Rockwell Medical's overall pharmaceutical sales.
  • Triferic Dialysate: Triferic Dialysate is an FDA-approved dialysate solution for use in peritoneal dialysis, indicated for iron maintenance and hemoglobin maintenance in adult patients with peritoneal dialysis-dependent chronic kidney disease (CKD). Competitors include Baxter International and Fresenius Medical Care who provide solutions for peritoneal dialysis.

Market Dynamics

industry overview logo Industry Overview

The renal disease market is driven by the increasing prevalence of diabetes and hypertension, major causes of kidney failure. This market includes pharmaceuticals, dialysis equipment, and services. Demand is high due to the chronic nature of the disease and an aging population.

Positioning

Rockwell Medical is positioned as a specialized pharmaceutical company focused on innovative iron therapies to improve outcomes for dialysis patients. Their key differentiator is Triferic, a product designed to deliver iron while minimizing ESA use and associated risks. They position themselves as a leader in iron maintenance therapy.

Total Addressable Market (TAM)

The global dialysis market is estimated at over $90 billion. Rockwell Medical, with Triferic products, targets the iron management portion of this market, representing a portion of this TAM. The peritoneal dialysis market, in particular, is expected to grow which gives Rockwell significant opportunity.

Upturn SWOT Analysis

Strengths

  • FDA-approved, differentiated Triferic product line
  • Specialized expertise in iron management for dialysis patients
  • Focus on addressing a significant unmet need in the renal disease market
  • Potential for expansion into new indications or delivery methods

Weaknesses

  • Reliance on a limited product portfolio
  • Small market capitalization may limit access to capital
  • Dependence on regulatory approvals and reimbursement
  • Historically unprofitable

Opportunities

  • Expanding Triferic into new markets or geographies
  • Developing new formulations or delivery methods for Triferic
  • Acquiring or partnering with other companies in the renal disease space
  • Increasing awareness and adoption of Triferic among healthcare providers

Threats

  • Competition from established dialysis providers and pharmaceutical companies
  • Changes in reimbursement policies or regulatory requirements
  • Generic entry of Triferic
  • Clinical trial failures or adverse events

Competitors and Market Share

competitor logo Key Competitors

  • BMY
  • VIF.SW
  • BAX
  • FMS

Competitive Landscape

Rockwell Medical faces competition from larger, more established companies in both the dialysis and pharmaceutical markets. Its advantage lies in its specialized focus and potentially differentiated product.

Growth Trajectory and Initiatives

Historical Growth: Historically, growth was tied to dialysis products and services, but with the divestiture, future growth depends primarily on Triferic products. Growth has been hindered by financial challenges.

Future Projections: Future growth is expected to depend on increasing sales of Triferic products. Analyst estimates are not readily available, but company management aims to achieve profitability through increased market penetration and cost management.

Recent Initiatives: The divestiture of the dialysis business to Baxter International in 2023. Focus on the Triferic product line.

Summary

Rockwell Medical is a biopharmaceutical company navigating a complex transition after selling its dialysis business. The company's success hinges on the growth of Triferic and its ability to effectively compete against larger players in the renal disease space. It has a product with a differentiated mechanism that offers several advantages. While the company has a unique product and a market need, it should monitor and watch out for changes in the industry, new entrants into the market and pricing pressures.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Rockwell Medical Inc. SEC Filings (10-K, 10-Q)
  • Company Press Releases
  • Investor Presentations
  • Third-party Market Research Reports
  • FDA Website
  • Company Website

Disclaimers:

This analysis is based on publicly available information and is for informational purposes only. It is not financial advice and should not be used as the sole basis for investment decisions. Market share data is approximate and may vary based on source and methodology. All financial data is based on publicly reported figures and may be subject to change.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Rockwell Medical Inc

Exchange NASDAQ
Headquaters Wixom, MI, United States
IPO Launch date 1998-01-27
President, CEO & Director Dr. Mark Strobeck Ph.D.
Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
Full time employees 244
Full time employees 244

Rockwell Medical, Inc., together with its subsidiaries, develops, manufactures, commercializes, and distributes various hemodialysis products for dialysis providers worldwide. The company offers citrapure citric acid concentrate, dri-sate dry acid concentrate, renalpure liquid acid concentrate, dri-sate acid concentrate mixer, renalpure acid concentrate, renalpure bicarbonate concentrate, sterilyte bicarbonate concentrate, centrisol and renasol hemodialysis concentrates, and dry acid concentrate mixer, as well as ancillary products, including 5% acetic acid, cleaner, citric acid descaler, water softener salt pellets, and other supplies used by hemodialysis providers. Its hemodialysis concentrate products are used to sustain patient's life by removing toxins and balancing electrolytes in a dialysis patient's bloodstream. The company serves to hemodialysis clinics, including dialysis concentrates, dialysis kits, and other ancillary products used in the dialysis process. Rockwell Medical, Inc. was formerly known as Rockwell Medical Technologies, Inc. and changed its name to Rockwell Medical, Inc. in June 2012. Rockwell Medical, Inc. was incorporated in 1996 and is headquartered in Wixom, Michigan.